Monday, August 24, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· June 4, 2026

GILEAD SCIENCES EN LAKEFRONT RONDEN DE OVERNAME VAN OURO MEDICINES AF OM DE PIJPLIJN OP HET GEBIED VAN ONTSTEKINGEN VERDER UIT TE BREIDEN

View original at globenewswire.com
GILEAD SCIENCES EN LAKEFRONT RONDEN DE OVERNAME VAN OURO MEDICINES AF OM DE PIJPLIJN OP HET GEBIED VAN ONTSTEKINGEN VERDER UIT TE BREIDEN Bedrijven gaan samenwerken aan de ontwikkeling van gamgertamig, een potentieel first-in-class en best-in-class T-cel-engager voor auto-immuunziekten Foster City, Californië en Mechel…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The addition of gamgertamig builds on Gilead's long-term strategy of investing in differentiated science and accelerating the development of therapies that address a significant unmet need

    60% confidence

  • Gamgertamig is expected to enter registration studies in 2027

    60% confidence

  • The transaction allows Lakefront to deploy at least $500 million of available cash independently of Gilead and outside the OLCA and Ouro transaction framework, including up to $150 million for share buybacks

    60% confidence

  • The Ouro acquisition, combined with existing expertise in immunology and cell therapy, supports Gilead's ambition to shift treatment paradigms from the management of chronic diseases toward the potential for a durable immune reset

    60% confidence

  • The Ouro portfolio will form the basis of Lakefront's R&D pipeline

    60% confidence

  • After the transaction, Lakefront will still have the majority of its cash available for additional strategic transactions and other capital allocation priorities

    60% confidence

  • Gilead is active in more than 35 countries worldwide

    60% confidence

  • Lakefront's cash balance is expected to be approximately €2 billion at end of 2026

    60% confidence

  • In 2025, Gilead announced a planned investment of $32 billion to further strengthen its US presence and drive the next phase of discoveries, employment and public health preparedness

    60% confidence

  • Gamgertamig has the potential to be a first-in-class and best-in-class T-cell engager for auto-immune diseases

    60% confidence

  • Gamgertamig is designed to enable rapid and deep depletion of plasma cells and B-cells following a limited subcutaneously administered treatment course, with the potential to induce durable disease control in severe antibody-mediated rare diseases

    60% confidence

Cited in these Via News reports